Urothelial Carcinoma

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Dr. Elizabeth Plimack, MD, MS, FASCO, is a Professor of Medical Oncology and the Deputy Director of Fox Chase Cancer Center. A recognized leader in the treatment of genitourinary malignancies, Dr. Plimack’s work primarily focuses on bladder and kidney cancers. At Fox Chase Cancer Center, Dr. Plimack and her team have pioneered an innovative approach to bladder preservation in patients with muscle-invasive bladder cancer (MIBC). Through clinical trials like RETAIN-1 and RETAIN-2, they are challenging traditional treatment paradigms by exploring systemic therapy-based strategies as alternatives to radical ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News